{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:48:41Z","timestamp":1762508921763,"version":"build-2065373602"},"reference-count":27,"publisher":"Mattioli1885","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: Pustular psoriasis (PP) is a rare life-threatening skin disease with negatively impact on quality of life (QoL). Clinically, it may be systemic (generalized pustular psoriasis [GPP]) or localized on palms and soles (palmoplantar pustulosis [PPP]). It is not rare to observe plaque psoriasis associated with GPP. Objective: We explored the therapies used for PP and their correlation with patient QoL scores, through a cross-sectional study using retrospective data from a monocentric database in the period 2017-2021. Method: Patient characteristics were summarized using descriptive statistics and treatment predictors of QoL were identified by multiple regression analysis. Among 108 patients with PP, 57.4% had GPP + PSO whereas 42.6% had PPP. The therapeutic management is based on systemic conventional treatments and biological therapies in both GPP and PPP. Results: GPP + PSO patients with an impaired QoL (DLQI\u226510) were associated with biological therapy including certolizumab (OR=2.38), etanercept (OR=2.25), secukinumab (OR=2.03) or ustekinumab (OR=2.79) whereas, PPP patients were positively associated with secukinumab (OR=2.85) or apremilast (OR 4.28, 95%-CI 0.56-9.62). Conclusion: Currently, systemic conventional therapy remains the therapeutic fulcrum of PP management. A great effect on QoL, especially for GPP+PSO, was assessed regardless the ongoing treatment and only newer biologic options were able to somehow positively impact.<\/jats:p>","DOI":"10.5826\/dpc.1501a4871","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:44:39Z","timestamp":1738154679000},"page":"4871","source":"Crossref","is-referenced-by-count":0,"title":["Real-Life Analysis of Therapeutic Management and Its Correlation With the Dermatology Life Quality Index Score in 108 Patients With Pustular Psoriasis: An Italian Monocenter Study"],"prefix":"10.5826","volume":"15","author":[{"given":"Dario","family":"Buononato","sequence":"first","affiliation":[{"name":"Unit of Dermatology, University of Campania \u201cLuigi Vanvitelli\u201d, Naples, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuele","family":"Scala","sequence":"first","affiliation":[{"name":"Division of Dermatology and Venereology, Department of Medicine Solna, and Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden ; Department of Dermatology and Venereology, Medical Center, University of Freiburg, Faculty of Medicine, University of Freiburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfrancesco","family":"Benvenuto","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli studi della campania Luigi Vanvitelli"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Caccavale","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli studi della campania Luigi Vanvitelli"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugenia Veronica","family":"Di Brizzi","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli studi della campania Luigi Vanvitelli"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Di Caprio","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli studi della campania Luigi Vanvitelli"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Argenziano","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli studi della campania Luigi Vanvitelli"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Balato","sequence":"first","affiliation":[{"name":"Universit\u00e0 degli studi della campania Luigi Vanvitelli"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"10.5826\/dpc.1501a4871_ref1","doi-asserted-by":"crossref","unstructured":"Reich K, Augustin M, Gerdes S, et al. Generalized pustular psoriasis: overview of the status quo and results of a panel discussion. J Dtsch Dermatol Ges. 2022;20:753-771. DOI: 10.1111\/ddg.14764. PMID: 35674482.","DOI":"10.1111\/ddg.14764"},{"key":"10.5826\/dpc.1501a4871_ref2","doi-asserted-by":"crossref","unstructured":"Reisner DV, Johnsson FD, Kotowsky N, Brunette S, Valdecantos W, Eyerich K. Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey. Am J Clin Dermatol. 2022;23(Suppl 1):65-71. DOI: 10.1007\/s40257-021-00663-y.","DOI":"10.1007\/s40257-021-00663-y"},{"key":"10.5826\/dpc.1501a4871_ref3","doi-asserted-by":"crossref","unstructured":"Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021-1026. DOI: 10.1016\/j.jaci.2018.06.038.","DOI":"10.1016\/j.jaci.2018.06.038"},{"key":"10.5826\/dpc.1501a4871_ref4","doi-asserted-by":"crossref","unstructured":"Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA, Marzano AV. Pustular Psoriasis: From Pathophysiology to Treatment. Biomedicines. 2021;9(12):1746. DOI: 10.3390\/biomedicines9121746.","DOI":"10.3390\/biomedicines9121746"},{"key":"10.5826\/dpc.1501a4871_ref5","doi-asserted-by":"crossref","unstructured":"Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (Review). Int J Mol Med. 2021;47(4):118. DOI: 10.3892\/ijmm.2021.4951.","DOI":"10.3892\/ijmm.2021.4951"},{"key":"10.5826\/dpc.1501a4871_ref6","doi-asserted-by":"crossref","unstructured":"M\u00f6ssner R, Wilsmann-Theis D, Oji V, et al. The genetic basis for most patients with pustular skin disease remains elusive. Br J Dermatol. 2018;178(3):740-748. DOI: 10.1111\/bjd.15867.","DOI":"10.1111\/bjd.15867"},{"key":"10.5826\/dpc.1501a4871_ref7","doi-asserted-by":"crossref","unstructured":"Sugiura K, Muto M, Akiyama M. CARD14 c.526G>C (p.Asp176His) is a significant risk factor for generalized pustular psoriasis with psoriasis vulgaris in the Japanese cohort. J Invest Dermatol. 2014;134(6):1755-1757. DOI: 10.1038\/jid.2014.46.","DOI":"10.1038\/jid.2014.46"},{"key":"10.5826\/dpc.1501a4871_ref8","doi-asserted-by":"crossref","unstructured":"Li L, You J, Fu X, et al. Variants of CARD14 are predisposing factors for generalized pustular psoriasis (GPP) with psoriasis vulgaris but not for GPP alone in a Chinese population. Br J Dermatol. 2019;180(2):425-426. DOI: 10.1111\/bjd.17392.","DOI":"10.1111\/bjd.17392"},{"key":"10.5826\/dpc.1501a4871_ref9","doi-asserted-by":"crossref","unstructured":"Menter A, Van Voorhees AS, Hsu S. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. Dermatol Ther (Heidelb). 2021;11(6):1917-1929. DOI: 10.1007\/s13555-021-00612-x.","DOI":"10.1007\/s13555-021-00612-x"},{"key":"10.5826\/dpc.1501a4871_ref10","doi-asserted-by":"crossref","unstructured":"Blair HA. Spesolimab: First Approval. Drugs. 2022;82(16):1681-1686. DOI: 10.1007\/s40265-022-01801-4.","DOI":"10.1007\/s40265-022-01801-4"},{"key":"10.5826\/dpc.1501a4871_ref11","doi-asserted-by":"crossref","unstructured":"Morita A, Choon SE, Bachelez H, et al. Design of Effisayil\u2122 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis. Dermatol Ther (Heidelb). 2023;13(2):347-359. DOI: 10.1007\/s13555-022-00835-6.","DOI":"10.1007\/s13555-022-00835-6"},{"key":"10.5826\/dpc.1501a4871_ref12","doi-asserted-by":"crossref","unstructured":"Iznardo H, Puig L. Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. Int J Mol Sci. 2021;22(9):4344. DOI: 10.3390\/ijms22094344.","DOI":"10.3390\/ijms22094344"},{"key":"10.5826\/dpc.1501a4871_ref13","unstructured":"Khanskaya I, Pinkstaff J, Marino MH, Savall T, Li J, Londei M. A Phase 1 Study of ANB019, an Anti-IL-36 Receptor Monoclonal Antibody, in Healthy Volunteers. AnaptysBio. 2018. Disponibile su: https:\/\/www2.anaptysbio.com\/wp-content\/uploads\/ANB019-Phase-1-Study-Poster-EAACI-2018.pdf."},{"key":"10.5826\/dpc.1501a4871_ref14","doi-asserted-by":"crossref","unstructured":"Burden AD, Choon SE, Gottlieb AB, Navarini AA, Warren RB. Clinical Disease Measures in Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):39-50. DOI: 10.1007\/s40257-021-00653-0.","DOI":"10.1007\/s40257-021-00653-0"},{"key":"10.5826\/dpc.1501a4871_ref15","doi-asserted-by":"crossref","unstructured":"Bhushan M, Burden AD, McElhone K, James R, Vanhoutte FP, Griffiths CE. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2001;145(3):546-553. DOI: 10.1046\/j.1365-2133.2001.04411.x.","DOI":"10.1046\/j.1365-2133.2001.04411.x"},{"key":"10.5826\/dpc.1501a4871_ref16","doi-asserted-by":"crossref","unstructured":"Scala E, Megna M, Amerio P, et al. Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS One. 2020;15(8):e0237267. DOI: doi:10.1371\/journal.pone.0237267.","DOI":"10.1371\/journal.pone.0237267"},{"key":"10.5826\/dpc.1501a4871_ref17","doi-asserted-by":"crossref","unstructured":"Tosukhowong T, Kiratikanon S, Wonglamsam P, et al. Epidemiology and clinical features of pustular psoriasis: A 15-year retrospective cohort. J Dermatol. 2021;48(12):1931-1935. DOI: 10.1111\/1346-8138.16164.","DOI":"10.1111\/1346-8138.16164"},{"key":"10.5826\/dpc.1501a4871_ref18","doi-asserted-by":"crossref","unstructured":"Pfohler C, Muller CS, Vogt T. Psoriasis vulgaris and psoriasis pustulosa: epidemiology, quality of life, comorbidities and treatment. Curr Rheumatol Rev. 2013;9(1):2-7. DOI:10.2174\/1573397111309010002.","DOI":"10.2174\/1573397111309010002"},{"key":"10.5826\/dpc.1501a4871_ref19","doi-asserted-by":"crossref","unstructured":"Lu J, Wang Y, Li Y, Gong Y, Ding Y, Shi Y. Comparative study on the clinical efficacy and safety of acitretin and MTX in the treatment of pustular psoriasis by TLR7\/MyD88\/CXCL16 pathway. Appl Bionics Biomech. 2022;2022:9640326. DOI: Published 2022 Mar 18. doi:10.1155\/2022\/9640326.","DOI":"10.1155\/2022\/9640326"},{"key":"10.5826\/dpc.1501a4871_ref20","doi-asserted-by":"crossref","unstructured":"Wang WM, Jin HZ. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19(8):969-980. DOI: 10.1080\/14740338.2020.1785427.","DOI":"10.1080\/14740338.2020.1785427"},{"key":"10.5826\/dpc.1501a4871_ref21","doi-asserted-by":"crossref","unstructured":"Gottlieb AB, Kubanov A, van Doorn M, et al. Sustained efficacy of secukinumab in patients with moderate-to-severe palmoplantar psoriasis: 2.5-year results from GESTURE, a randomized, double-blind, placebo-controlled trial. Br J Dermatol. 2020;182(4):889-899. DOI: 10.1111\/bjd.18331.","DOI":"10.1111\/bjd.18331"},{"key":"10.5826\/dpc.1501a4871_ref22","doi-asserted-by":"crossref","unstructured":"Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86(6):1266-1274. DOI:10.1016\/j.jaad.2021.06.008.","DOI":"10.1016\/j.jaad.2021.06.008"},{"key":"10.5826\/dpc.1501a4871_ref23","doi-asserted-by":"crossref","unstructured":"Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645-1651. DOI: 10.1111\/jdv.14949.","DOI":"10.1111\/jdv.14949"},{"key":"10.5826\/dpc.1501a4871_ref24","doi-asserted-by":"crossref","unstructured":"Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016;17(4):349-358. DOI: 10.1007\/s40257-016-0191-7.","DOI":"10.1007\/s40257-016-0191-7"},{"key":"10.5826\/dpc.1501a4871_ref25","doi-asserted-by":"crossref","unstructured":"Husson B, Barbe C, Hegazy S, et al; Groupe de Recherche sur le Psoriasis de la Soci\u00e9t\u00e9 Fran\u00e7aise de Dermatologie. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020;34(10):2330-2338. DOI: 10.1111\/jdv.16265.","DOI":"10.1111\/jdv.16265"},{"key":"10.5826\/dpc.1501a4871_ref26","doi-asserted-by":"crossref","unstructured":"Ferri\u00e8res L, Konstantinou MP, Bulai Livideanu C, et al. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. Clin Exp Dermatol. 2019;44(7):e230-e234. DOI: 10.1111\/ced.13999.","DOI":"10.1111\/ced.13999"},{"key":"10.5826\/dpc.1501a4871_ref27","doi-asserted-by":"crossref","unstructured":"Kearns DG, Chat VS, Zang PD, Han G, Wu JJ. Review of treatments for generalized pustular psoriasis. J Dermatolog Treat. 2021;32(5):492-494. DOI:10.1080\/09546634.2019.1682502.","DOI":"10.1080\/09546634.2019.1682502"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/4871\/3002","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/4871\/3464","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/download\/4871\/3002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:33:15Z","timestamp":1762507995000},"score":1,"resource":{"primary":{"URL":"https:\/\/mail.dpcj.org\/index.php\/dpc\/article\/view\/4871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1501a4871","relation":{"has-manifestation":[{"id-type":"other","id":"1-78-4871-g3002","asserted-by":"subject"},{"id-type":"other","id":"1-78-4871-g3464","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.v15i1","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"type":"electronic","value":"2160-9381"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"article-number":"12"}}